CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Avastin +2 moredrug
Likely dose
Avastin 15mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00511992
NCT00511992Phase 2Completed
CompareCT.gov

Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer

University of Oklahoma·interventional·Posted Aug 6, 2007·Updated Jul 2, 2017

In Brief

A Phase 2 clinical trial evaluating Avastin, Paclitaxel, and 1 other intervention for Advanced Ovarian Carcinoma and 2 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Carcinosarcoma
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 6, 2007
Enrollment StartJul 1, 2007
Primary CompletionAug 3, 2015
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 18.9 years ago

Interventions

Avastindrug

Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2) Consolidation Treatment: Avastin 15mg/kg IV every 21 days x 12 cycles

Paclitaxeldrug

Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles

Cisplatindrug

75mg/m2 IP day 2 every 21 days x 6 cycles